Literature DB >> 27226954

Emerging roles of FGF signaling in hepatocellular carcinoma.

Nana Zheng1, Wenyi Wei2, Zhiwei Wang1.   

Abstract

Entities:  

Year:  2016        PMID： 27226954      PMCID： PMC4876964     

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  53 in total

Review 1.  Targeting fibroblast growth factor receptor pathway in breast cancer.

Authors:  Carmen Criscitiello; Angela Esposito; Sabino De Placido; Giuseppe Curigliano
Journal:  Curr Opin Oncol       Date:  2015-11       Impact factor: 3.645

2.  Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling.

Authors:  Corentin Herbert; Ulrich Schieborr; Krishna Saxena; Jarek Juraszek; Frederik De Smet; Chantal Alcouffe; Marc Bianciotto; Giorgio Saladino; David Sibrac; Denis Kudlinzki; Sridhar Sreeramulu; Alan Brown; Patrice Rigon; Jean-Pascal Herault; Gilbert Lassalle; Tom L Blundell; Frederic Rousseau; Ann Gils; Joost Schymkowitz; Peter Tompa; Jean-Marc Herbert; Peter Carmeliet; Francesco Luigi Gervasio; Harald Schwalbe; Françoise Bono
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

3.  Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

Authors:  Christine Gauglhofer; Sandra Sagmeister; Waltraud Schrottmaier; Carina Fischer; Chantal Rodgarkia-Dara; Thomas Mohr; Stefan Stättner; Christoph Bichler; Daniela Kandioler; Fritz Wrba; Rolf Schulte-Hermann; Klaus Holzmann; Michael Grusch; Brigitte Marian; Walter Berger; Bettina Grasl-Kraupp
Journal:  Hepatology       Date:  2011-02-11       Impact factor: 17.425

Review 4.  Emerging roles of Notch signaling in liver disease.

Authors:  Fabian Geisler; Mario Strazzabosco
Journal:  Hepatology       Date:  2014-09-19       Impact factor: 17.425

Review 5.  Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.

Authors:  Cinta Hierro; Jordi Rodon; Josep Tabernero
Journal:  Semin Oncol       Date:  2015-09-24       Impact factor: 4.929

Review 6.  Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.

Authors:  Matthias S Matter; Thomas Decaens; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  J Hepatol       Date:  2013-12-03       Impact factor: 25.083

Review 7.  FGFR as potential target in the treatment of squamous non small cell lung cancer.

Authors:  Marcello Tiseo; Francesco Gelsomino; Roberta Alfieri; Andrea Cavazzoni; Cecilia Bozzetti; Anna Maria De Giorgi; Pier Giorgio Petronini; Andrea Ardizzoni
Journal:  Cancer Treat Rev       Date:  2015-05-01       Impact factor: 12.111

8.  Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.

Authors:  Dorothy M French; Benjamin C Lin; Manping Wang; Camellia Adams; Theresa Shek; Kathy Hötzel; Brad Bolon; Ronald Ferrando; Craig Blackmore; Kurt Schroeder; Luis A Rodriguez; Maria Hristopoulos; Rayna Venook; Avi Ashkenazi; Luc R Desnoyers
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

Review 9.  TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review).

Authors:  Katsunori Yoshida; Miki Murata; Takashi Yamaguchi; Koichi Matsuzaki
Journal:  Int J Oncol       Date:  2014-07-22       Impact factor: 5.650

Review 10.  Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers.

Authors:  Francesca M Trovato; Joshua M Tognarelli; Mary Me Crossey; Daniela Catalano; Simon D Taylor-Robinson; Guglielmo M Trovato
Journal:  World J Hepatol       Date:  2015-11-18
View more
  13 in total

1.  Impact of Obeticholic acid Exposure on Decompensation and Mortality in Primary Biliary Cholangitis and Cirrhosis.

Authors:  Binu V John; Kaley Schwartz; Cynthia Levy; Bassam Dahman; Yangyang Deng; Paul Martin; Tamar H Taddei; David E Kaplan
Journal:  Hepatol Commun       Date:  2021-05-06

Review 2.  Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.

Authors:  Min Li; Weiyue Zhang; Birong Wang; Yang Gao; Zifang Song; Qi Chang Zheng
Journal:  Int J Nanomedicine       Date:  2016-10-31

3.  Diminished gallbladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-deficient mice.

Authors:  Kunrong Cheng; Melissa Metry; Jessica Felton; Aaron C Shang; Cinthia B Drachenberg; Su Xu; Min Zhan; Justin Schumacher; Grace L Guo; James E Polli; Jean-Pierre Raufman
Journal:  Oncotarget       Date:  2018-05-22

4.  Incompatibility of the circadian protein BMAL1 and HNF4α in hepatocellular carcinoma.

Authors:  Baharan Fekry; Aleix Ribas-Latre; Corrine Baumgartner; Jonathan R Deans; Christopher Kwok; Pooja Patel; Loning Fu; Rebecca Berdeaux; Kai Sun; Mikhail G Kolonin; Sidney H Wang; Seung-Hee Yoo; Frances M Sladek; Kristin Eckel-Mahan
Journal:  Nat Commun       Date:  2018-10-19       Impact factor: 14.919

Review 5.  Deciphering Platelet Kinetics in Diagnostic and Prognostic Evaluation of Hepatocellular Carcinoma.

Authors:  Bibek Aryal; Munekazu Yamakuchi; Toshiaki Shimizu; Jun Kadono; Akira Furoi; Kentaro Gejima; Teruo Komokata; Teruto Hashiguchi; Yutaka Imoto
Journal:  Can J Gastroenterol Hepatol       Date:  2018-06-27

Review 6.  FGF19-FGFR4 Signaling in Hepatocellular Carcinoma.

Authors:  Aroosha Raja; Inkeun Park; Farhan Haq; Sung-Min Ahn
Journal:  Cells       Date:  2019-06-04       Impact factor: 6.600

7.  Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization.

Authors:  Hyeon Jeong Yoon; Je Moon Woo; Yong Sok Ji; Kyung Chul Yoon
Journal:  Medicina (Kaunas)       Date:  2019-11-07       Impact factor: 2.430

8.  Large-scale discovery of previously undetected microRNAs specific to human liver.

Authors:  Brenda C Minatel; Victor D Martinez; Kevin W Ng; Adam P Sage; Tomas Tokar; Erin A Marshall; Christine Anderson; Katey S S Enfield; Greg L Stewart; Patricia P Reis; Igor Jurisica; Wan L Lam
Journal:  Hum Genomics       Date:  2018-03-27       Impact factor: 4.639

9.  Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma.

Authors:  Takahiro Maeda; Hiroaki Kanzaki; Tetsuhiro Chiba; Junjie Ao; Kengo Kanayama; Susumu Maruta; Yuko Kusakabe; Tomoko Saito; Kazufumi Kobayashi; Soichiro Kiyono; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Shingo Nakamoto; Ryo Nakagawa; Ryosuke Muroyama; Tatsuo Kanda; Hitoshi Maruyama; Naoya Kato
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

10.  Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.

Authors:  Aldo Prawira; Thi Bich Uyen Le; Thanh Chung Vu; Hung Huynh
Journal:  Liver Int       Date:  2020-11-23       Impact factor: 5.828
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.